Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKD1 | Q15139 | 14/20 | 0.70 |
| ▸ | MELK | Q14680 | 1/20 | 0.58 |
| ▸ | FLT3 | P36888 | 3/20 | 0.53 |
| ▸ | KDR | P35968 | 1/20 | 0.53 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.50 |
| ▸ | RAF1 | P04049 | 1/20 | 0.48 |
| ▸ | BRAF | P15056 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL936647 | 0.94 | PRKD1 (0.75) | PRKD1MELKFLT3KDRMAP4K1 | |
| SCHEMBL6923976 | 0.92 | PRKD1 (0.74) | PRKD1MELKFLT3KDRMAP4K1 | |
| SCHEMBL998233 | 0.84 | PRKD1 (0.74) | PRKD1MELKFLT3KDRMAP4K1 | |
| SCHEMBL958990 | 0.83 | PRKD1 (1.00) | PRKD1MELKFLT3KDRMAP4K1 | |
| SCHEMBL6922963 | 0.83 | PRKD1 (1.00) | PRKD1MELKFLT3KDRMAP4K1 | |
| SCHEMBL1083327 | 0.82 | PRKD1 (1.00) | PRKD1MELK | |
| SCHEMBL6923792 | 0.82 | PRKD1 (0.81) | PRKD1MELKFLT3MAP4K1 | |
| SCHEMBL6924262 | 0.81 | PRKD1 (1.00) | PRKD1MELKFLT3MAP4K1 | |
| SCHEMBL937642 | 0.81 | PRKD1 (0.77) | PRKD1MELKFLT3KDRMAP4K1 | |
| SCHEMBL1081001 | 0.81 | PRKD1 (0.73) | PRKD1MELKFLT3KDRMAP4K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011009484-A1 | ARYLPYRAZOLES AND ARYLISOXAZOLES AND THEIR USE AS PKD MODULATORS | NOVARTIS AG (CH) | 2011-01-27 | — | — | WO | disclosed |
| WO-2011009484-A1 | ARYLPYRAZOLES AND ARYLISOXAZOLES AND THEIR USE AS PKD MODULATORS | NOVARTIS AG (CH) | 2011-01-27 | — | — | WO | disclosed |